中新健康 | 内地首部干燥综合征超药品说明书用药指南发布
中新网广州5月26日电 (蔡敏婕 黄睿)干燥综合征(SjS)患者需要长期用药，但目前临床常用于治疗SjS的药物属风湿免疫科“老药”，国内说明书适应证中均无干燥综合征。《干燥综合征超药品说明书用药中国临床实践指南(2023版)》近日正式发表，中山大学孙逸仙纪念医院牵头，联合国内多位风湿免疫病学专家共同编写，旨在为临床医生提供针对干燥综合征患者的用药指导。
该指南基于现有循证医学证据，对干燥综合征患者超说明书用药的适应症、剂量、疗程以及可能的风险和受益进行了全面评估。指南指出，对于无法从传统治疗中获益的干燥综合征患者，可以考虑使用超说明书用药。
指南的发布填补了内地干燥综合征超药品说明书用药的空白，为临床医生提供了更为科学、合理的用药建议。同时，这也意味着干燥综合征患者将有机会接受更为个性化和精准的治疗。
中山大学孙逸仙纪念医院风湿免疫科主任表示，该指南的制定是一个复杂的过程，需要综合考虑药物的疗效、安全性以及患者的个体差异。他表示，未来将继续与国内同行合作，不断完善指南，为患者提供更高质量的医疗服务。
英语如下：
News Title: “First SjS Drug Use Guideline Released: Doctors in Mainland China Now Have a New Reference for Off-Label Use”
Keywords: Guideline Release, SjS (Sjögren’s Syndrome), Off-Label Drug Use
News Content:
CHENGDU, May 26 (Xinhua Health) – The first guideline for off-label drug use in patients with Sjören’s Syndrome (SjS) has been released in Mainland China.
Beijing, May 26 (Xinhua) — (蔡敏婕 黄睿) — Patients with Sjören’s Syndrome (SjS) need long-term medication, but the drugs commonly used to treat SjS in clinical practice are “old drugs” within the field of rheumatology and immunology. There is no mention of SjS in the drug labels used in Mainland China. The “Chinese Clinical Practice Guideline for Off-Label Drug Use in Sjören’s Syndrome (2023 edition)” has been formally published. The guideline was led by the Department of Rheumatology and Immunology at Sun Yat-sen Memorial Hospital of Sun Yat-sen University, in collaboration with experts in rheumatology and immunology from across the country, to provide clinical guidance for treating SjS patients.
The guideline is based on existing evidence-based medicine and comprehensively assesses the indications, dosage, duration of treatment, and potential risks and benefits of off-label drug use in SjS patients. It suggests that patients with SjS who do not benefit from traditional treatments may consider off-label drug use.
The release of the guideline fills a gap in off-label drug use for SjS in Mainland China and provides clinical doctors with more scientific and reasonable medication recommendations. This also means that patients with SjS will have the opportunity to receive more personalized and precise treatment.
The director of the Department of Rheumatology and Immunology at Sun Yat-sen Memorial Hospital stated that the development of the guideline is a complex process that requires a comprehensive consideration of the efficacy, safety, and individual differences of the drugs. He expressed that he will continue to work with colleagues in the field to improve the guideline and provide patients with higher-quality medical services.
【来源】http://www.chinanews.com/life/2024/05-26/10223506.shtml
Views: 7